Parse Biosciences Launches New Barcoding Technology for Improved Single-Cell Analysis of Archived Tissue
SEATTLE - November 18, 2023 – Parse Biosciences today announced the release of a new, formaldehyde-fixed paraffin-embedded (FFPE)-compatible barcoding technology designed to significantly enhance single-cell analysis of the whole transcriptome. This innovation expands the submission of Parse’s platform to a wider range of sample types, including valuable archived clinical samples, accelerating research in areas like cancer and disease pathology.
the new technology addresses a critical challenge in single-cell sequencing: the degradation of RNA in FFPE-preserved tissues, a standard practice for long-term sample storage in clinical settings. By optimizing barcoding chemistry, Parse enables researchers to obtain high-quality data from these previously difficult-to-analyse samples, unlocking insights from a vast repository of existing biobanks.
Founded on technology developed at the University of Washington by Alex Rosenberg and Charles Roco, Parse Biosciences enables researchers to sequence single cells at an unprecedented scale and efficiency. The company’s products have already contributed to groundbreaking discoveries in cancer treatment, tissue regeneration, stem cell therapy, kidney and liver diseases, brain advancement, and the immune system.
parse’s growing product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and the interactive data analysis solution, Trailmaker. The company has raised over $100 million in capital and currently serves over 3,000 customers globally.
Parse Biosciences is located in Seattle’s South Lake Union neighborhood, having recently moved into a new headquarters and state-of-the-art laboratory. More information can be found at https://www.parsebiosciences.com/.
contact:
katie Kramer
kkramer@parsebiosciences.com | 858.504.0455
